Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7366986 | 0.80 | HRH3 (0.45) | CHRNB2CHRNA4HRH3 | |
| SCHEMBL213916 | 0.76 | — | — | |
| SCHEMBL3056549 | 0.71 | — | — | |
| SCHEMBL162718 | 0.70 | HRH3 (0.56) | CHRNB2CHRNA4HRH3ALDH1A1TSHR | |
| SCHEMBL27625032 | 0.69 | HRH3 (0.54) | CHRNB2CHRNA4HRH3ALDH1A1TSHR | |
| SCHEMBL12910012 | 0.68 | CHRNB2 (0.53) | CHRNB2CHRNA4HRH3ALDH1A1TSHR | |
| SCHEMBL15516653 | 0.68 | MAOB (0.32) | — | |
| SCHEMBL4414485 | 0.68 | NOS2 (0.33) | NOS2 | |
| SCHEMBL7367240 | 0.68 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL974270 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024042361-A1 | TYK2 INHIBITORS AND USES THEREOF | SUDO BIOSCIENCES LIMITED (GB) | 2024-02-29 | — | — | WO | claimed |
| US-20130116230-A1 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2013-05-09 | — | — | US | claimed |
| US-8362003-B2 | 3-aminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2013-01-29 | — | — | US | claimed |
| EP-2431357-A2 | 3-Aminopyrrolidine Derivatives as Modulators of Chemokine Receptors | Incyte Corporation (US) | 2012-03-21 | — | — | EP | claimed |
| US-20110251168-A1 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION | 2011-10-13 | — | — | US | claimed |
| EP-1565436-A4 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORP (US) | 2007-07-18 | — | — | EP | claimed |
| US-20060252751-A1 | 3-Aminopyrrolidine derivaties as modulators of chemokine receptors | INCYTE HOLDINGS CORPORATION | 2006-11-09 | — | — | US | claimed |
| JP-2006516145-A | — | — | 2006-06-22 | — | — | JP | claimed |
| EP-1565436-A2 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2005-08-24 | — | — | EP | claimed |
| WO-2004050024-A2 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2004-06-17 | — | — | WO | claimed |
| US-5616711-A | REACTING BUTENE DERIVATIVE TO AN AMIDE DERIVATIVE; USEFUL AS INTERMEDIATES FOR PRODUCING ANTIULCER DRUGS | FUJIREBIO INC. (JP) | 1997-04-01 | — | — | US | claimed |
| EP-0582304-A2 | Methods of producing amino butene derivatives | FUJIREBIO Inc. (JP) | 1994-02-09 | — | — | EP | claimed |
| EP-0049173-B1 | PYRIMIDONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL DERIVATIVES CONTAINING THEM | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-07-03 | — | — | EP | claimed |
| US-4385058-A | HISTAMINE H2-ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1983-05-24 | — | — | US | claimed |
| EP-0049173-A2 | Pyrimidone derivatives, processes for their preparation and pharmaceutical derivatives containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1982-04-07 | — | — | EP | claimed |
| WO-2024042361-A1 | TYK2 INHIBITORS AND USES THEREOF | SUDO BIOSCIENCES LIMITED (GB) | 2024-02-29 | — | — | WO | disclosed |
| US-20170050942-A1 | 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORP (US) | 2017-02-23 | — | — | US | disclosed |
| US-4439609-A | 4-TERT-AMINOALKYL, 2-AMINOALKOXY OR 2-AMINOALKYLENETHIOALKYL SUBSTITUTED, CHEMICAL INTERMEDIATES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1984-03-27 | — | — | US | disclosed |
| US-4385058-A | HISTAMINE H2-ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1983-05-24 | — | — | US | disclosed |
| EP-0049173-A2 | Pyrimidone derivatives, processes for their preparation and pharmaceutical derivatives containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1982-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116230-A1 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR2, CXCR3, CCR5 | CHRNB2 2179/4885CHRNA4 988/4885HRH3 59/4885 |
| US-20060252751-A1 | 3-Aminopyrrolidine derivaties as modulators of chemokine receptors | CCR2, CXCR3, CCR5 | CHRNB2 2136/4885CHRNA4 891/4885HRH3 66/4885 |
| US-20110251168-A1 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR2, CXCR3, CCR5 | CHRNB2 2179/4885CHRNA4 988/4885HRH3 59/4885 |
| US-20170050942-A1 | 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR2, CCR5, CXCR3 | CHRNB2 2482/4885CHRNA4 1365/4885HRH3 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.